SGLT2 Inhibitors and Mechanisms of Hypertension

Briasoulis, Αlexandros; Dhaybi, Omar Al; Bakris, George L.

doi:10.1007/s11886-018-0943-5

Cited by 78 publications

(39 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Scattered reports suggested that there might be a risk for acute kidney injury (AKI) with the use of SGLT2is, which might occasionally require renal replacement therapy 219,220 . Several mechanisms have been proposed to explain a risk of AKI with SGLT2is ( Supplementary Box 1).…”

Section: Acute Kidney Injurymentioning

confidence: 99%

Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

2020

View full text Add to dashboard Cite

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex. Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic agents for T2DM. By targeting the kidney, they have a unique mechanism of action, which results in enhanced glucosuria, osmotic diuresis and natriuresis, thereby improving glucose control with a limited risk of hypoglycaemia and exerting additional positive effects such as weight loss and the lowering of blood pressure. Several outcome studies with canagliflozin, dapagliflozin or empagliflozin reported a statistically significant reduction in major cardiovascular events, hospitalization for heart failure and progression to advanced renal disease in patients with T2DM who have established atherosclerotic cardiovascular disease, several cardiovascular risk factors, albuminuric mild to moderate chronic kidney disease or heart failure. Current guidelines proposed a new paradigm in the management of T2DM, with a preferential place for SGLT2is, after metformin, in patients with atherosclerotic cardiovascular disease, heart failure and progressive kidney disease. Ongoing trials might extend the therapeutic potential of SGLT2is in patients with, but also without, T2DM. This Review provides an update of the current knowledge on SGLT2is, moving from their use as glucose-lowering medications to their new positioning as cardiovascular and renal protective agents.

show abstract

Section: Acute Kidney Injurymentioning

confidence: 99%

Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

2020

View full text Add to dashboard Cite

show abstract

“…It turns out that SGLT-2 inhibitors reduce systolic and diastolic pressure. It is believed that these drugs reduce sympathetic tension, increase osmotic diuresis and minimally increase natriuresis [41,42]. Such action additionally reduces the risk of cardiovascular events [43].…”

Section: Current Status and Future Perspectivementioning

confidence: 99%

The analysis of a wide spectrum of activity of Sodium-Glucose co-transporter-2 inhibitors. A literature review

Kozioł

Krasowska

Lewicki

et al. 2020

J Educ Health Sport

View full text Add to dashboard Cite

show abstract

“…In patients with type 2 diabetes, renal glucose transport thresholds are increased as compared to normal individuals as a result of SGLT2 upregulation. The intrinsic risk of hypoglycemia with SGLT2 inhibitors is expected to be low, because this effect is insulin independent, and the amount of urinary glucose excretion is determined in part by blood glucose concentrations [136][137][138][139].…”

Section: Sglt2 Inhibitorsmentioning

confidence: 99%

Diabetes Mellitus and Colon Carcinogenesis: Expectation for Inhibition of Colon Carcinogenesis by Oral Hypoglycemic Drugs

Kato

Shirakami

Shimizu

2019

Gastrointestinal Disorders

View full text Add to dashboard Cite

The global deaths due to colorectal cancer and diabetes mellitus have increased by 57% and 90%, respectively. The relationship between various cancers and diabetes mellitus has been shown in multiple epidemiological studies. Hence, better management of diabetes mellitus is expected to reduce the risk of various cancers. This review focuses on colorectal cancer and aims to summarize recent findings on the antitumor effects of various oral hypoglycemic drugs on colorectal cancer and their estimated mechanisms. Of the seven classes of oral hypoglycemic agents, only metformin was found to have suppressive effects on colorectal cancer in both clinical and basic research. Clinical and basic researches on suppressing effects of glinides, dipeptidyl peptidase-4 inhibitors, thiazolidinedione, α-glucosidase inhibitors, and sodium glucose cotransporter-2 inhibitors against colon carcinogenesis have been insufficient and have not arrived at any conclusion. Therefore, further research regarding these agents is warranted. In addition, the suppressive effects of these agents in healthy subjects without diabetes should also be investigated.

show abstract

SGLT2 Inhibitors and Mechanisms of Hypertension

Cited by 78 publications

References 53 publications

Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

The analysis of a wide spectrum of activity of Sodium-Glucose co-transporter-2 inhibitors. A literature review

Diabetes Mellitus and Colon Carcinogenesis: Expectation for Inhibition of Colon Carcinogenesis by Oral Hypoglycemic Drugs

Contact Info

Product

Resources

About